Login to Your Account

ESA Competition? Affymax Files Peginesatide NDA

By Trista Morrison

Wednesday, June 1, 2011
Shares of Affymax Inc. have yet to recover from the beating they took about a year ago when Phase III data for peginesatide (formerly Hematide) fell short of investor expectations, but that hasn't stopped the Palo Alto, Calif.-based biotech and partner Takeda Pharmaceutical Co. Ltd. from moving forward with a new drug application (NDA).

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription